21 reports

Immunotoxicity of monoclonal antibodies. mAbs; ##(##): ##-## Duan C, et al. (2015).

  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Biogen Idec Inc.
  • Johnson & Johnson
  • KEY UPDATES TO THE MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • OF CONTENTS

" I' m intrigued by the anti-tau monoclonal antibodies.

  • Dementia
  • Monoclonal Antibody
  • United States
  • Forecast
  • Biogen Idec Inc.

For example, anti-fibrillin-## antibodies can activate fibroblasts, and antibodies to matrix metalloproteinase-## (MMP-##) and MMP-## can prevent the breakdown of excessive collagen.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Monoclonal Antibody
  • Biogen Idec Inc.
  • 7.3 PRODUCT PROFILES - MONOCLONAL ANTIBODY INJECTABLE THERAPIES
  • LEADING DISEASE-MODIFYING DRUGS FOR THE TREATMENT OF MS, 2017

RANDOMIZED PHASE I TRIALS OF THE SAFETY/ TOLERABILITY OF ANTI-LINGO-## MONOCLONAL ANTIBODY BIIB##.

  • Monoclonal Antibody
  • Therapy
  • United States
  • Forecast
  • Biogen Idec Inc.

Monoclonal antibodies (mAbs) are the newest class of drugs, predominately used in the treatment of psoriasis.

  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Therapy
  • Biogen Idec Inc.
  • Sponsor(s)

FIGURE ##-##: MONOCLONAL ANTIBODIES IN CANCER TREATMENT, OPDIVO PERFORMANCE VS.

  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • World
  • Biogen Idec Inc.
  • NEURODEGENERATIVE DISORDERS, GLOBAL, CO-DEVELOPMENT DEALS VALUED ABOVE $100M, 2006-2016
  • NEURODEGENERATIVE DISORDERS, GLOBAL, ANNUAL REVENUE FOR KEY PRODUCTS ($BN), 2015-2022

Tysabri is a recombinant humanized immunoglobulin (IgG##) monoclonal antibody (mAb).

  • Clinical Trial
  • Dementia
  • Monoclonal Antibody
  • Therapy
  • Biogen Idec Inc.

PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF A HUMAN ANTI-IL-## monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Monoclonal Antibody
  • Biogen Idec Inc.
  • 4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE
  • IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

MONOCLONAL ANTIBODIES ARE MAINLY OF THREE TYPES SUCH AS NAKED MONOCLONAL ANTIBODIES, BISPECIFIC MONOCLONAL ANTIBODIES AND CONJUGATED MONOCLONAL ANTIBODIES.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Biogen Idec Inc.
  • COMPOUNDS THAT WERE RECENTLY DISCONTINUED IN FOLLICULAR LYMPHOMA
  • GAZYVA DRUG PROFILE

Lin TS (2010) Ofatumumab: a novel monoclonal anti-CD## antibody.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Biogen Idec Inc.

Alzheimer's disease

4385 5000 3900
  • PHASE III PIPELINE PRODUCTS IN DEVELOPMENT FOR ALZHEIMER'S DISEASE
  • Executive Summary

Aducanumab is an intravenous-infused, fully human recombinant immunoglobulin G## monoclonal antibody (MAb) (NIA, 2015; Alzforum, 2015).

  • Dementia
  • Mental Health
  • Monoclonal Antibody
  • Therapy
  • Biogen Idec Inc.

Antibody Cancer ## ## ID No.

  • Biosimilar
  • Monoclonal Antibody
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.

Multiple sclerosis

4385 5000 3900
  • PRODUCT PROFILE
  • Product profile (late stage): Zinbryta

Tysabri is a humanized monoclonal antibody against the cellular adhesion molecule alpha-integrin.

  • Healthcare
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • Biogen Idec Inc.

In January 2017, Biogen initiated a Phase ## trial of an anti-tau monoclonal antibody, BIIB##, in healthy volunteers and participants with Alzheimer' s disease.

  • Monoclonal Antibody
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • Biogen Idec Inc.
  • 5. All the trials included are unique trials.

While only an early look at the Week ## timepoint, the data continue to be impressive and suggestive of a highly efficacious anti-CD## monoclonal antibody with a manageable safety profile that can be administered in a convenient one-hour infusion.

  • Clinical Trial
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • Biogen Idec Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Interferon
  • Monoclonal Antibody
  • Neurological Disorder
  • Biogen Idec Inc.

RITUXAN / MABTHERA BIOSIMILAR ANTIBODIES - ##/ ## 2093 ## ID No.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Genentech, Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Monoclonal Antibody
  • Neurological Disorder
  • Neurology
  • Therapy
  • Biogen Idec Inc.
  • 5. All the trials included are unique trials.

Slawomir Jaros, PhD - Head of Operations and Science at Mabion S. A. : Published reports confirm the efficacy of the treatment of patients with multiple sclerosis with the use of antibodies reacting with B-lymphocytes.

  • Clinical Trial
  • Interferon
  • Monoclonal Antibody
  • Neurological Disorder
  • Biogen Idec Inc.
  • Latest Clinical Trials News on Relapsing Multiple Sclerosis (RMS)
  • Clinical Trial Profile Snapshots

About Ofatumumab Jun ##, 2016: New Data at CMSC Assess Real-World Impact of Rebif (interferon beta-##a) in People with Relapsing MS Ofatumumab is a human monoclonal antibody that is designed to target the CD## molecule found on the surface of normal B lymphocytes.

  • Interferon
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • Biogen Idec Inc.
  • Biogen, Inc. - Discontinued Pipeline Products
  • Biogen, Inc. - Discontinued Pipeline Products, 2016

STX-## is a humanized monoclonal antibody.

  • Immunotherapy
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Biogen Idec Inc.